Agent for preventing and/or treating tissue disruption-accompanied diseases
The present invention relates to an agent for preventing and/or treating diseases accompanied by tissue disruption, which comprises a polypeptide having granulocyte colony-stimulating factor activity as an active ingredient, and a medicament for mobilizing a multipotent stem cell from a tissue into peripheral blood, which comprises a polypeptide having granulocyte colony-stimulating factor activity as an active ingredient.
1 - 27 . (canceled)
28 . A method for preventing and/or treating diseases accompanied by tissue disruption, which comprises administering a polypeptide having granulocyte colony-stimulating factor activity.
29 . The method according to claim 28 , which comprises administering (a) the polypeptide having granulocyte colony-stimulating factor activity and (b) retinoic acid or a retinoic acid derivative simultaneously or separately by keeping a period.
30 . The method according to claim 28 , which comprises administering (a) the polypeptide having granulocyte colony-stimulating factor activity and (b) a CXCR4 inhibitor simultaneously or separately by keeping a period.
31 . A method for mobilizing a multipotent stem cell from a tissue into peripheral blood, which comprises administering a polypeptide having granulocyte colony-stimulating factor activity.
32 . The method according to claim 31 , which comprises administering (a) the polypeptide having granulocyte colony-stimulating factor activity and (b) retinoic acid or a retinoic acid derivative simultaneously or separately by keeping a period.
33 . The method according to claim 31 , which comprises (a) the polypeptide having granulocyte colony-stimulating factor activity and (b) a CXCR4 inhibitor simultaneously or separately by keeping a period.
34 - 35 . (canceled)
36 . The method according to claim 28 , wherein the polypeptide comprises the amino acid sequence represented by SEQ ID NO:1.
37 . The method according to claim 28 , wherein the polypeptide consists of an amino acid sequence in which at least one amino acid residue in the amino acid sequence represented by SEQ ID NO:1 is deleted, substituted and/or added, and has granulocyte colony-stimulating factor activity.
38 . The method according to claim 28 , wherein the polypeptide consists of an amino acid sequence having a homology of 80% or more with the amino acid sequence represented by SEQ ID NO:1, and has granulocyte colony-stimulating factor activity.
39 . The method according to claim 28 , wherein the polypeptide is a chemically modified polypeptide having granulocyte colony-stimulating factor activity.
40 . The method according to claim 39 , wherein the polypeptide is modified with polyalkylene glycol.
41 . The method according to claim 30 , wherein the CXCR4 inhibitor is AMD-3100 or a derivative thereof.
42 . The method according to claim 28 , wherein the disease accompanied by tissue disruption is selected from the group consisting of nervous diseases, circulatory organ system diseases, hepatic diseases, pancreatic diseases, digestive tract system diseases, renal diseases, skin diseases and lung diseases.
43 . The method according to claim 42 , wherein the nervous disease is selected from the group consisting of cerebral infarction, cerebrovascular accidents, Parkinson disease, Alzheimer disease, Huntington chorea, spinal cord injury, depression and manic-depressive psychosis.
44 . The method according to claim 42 , wherein the circulatory organ system disease is selected from the group consisting of obstructive vascular disease, myocardial infarction, cardiac failure and coronary artery disease.
45 . The method according to claim 42 , wherein the hepatic disease is selected from the group consisting of hepatitis, hepatic cirrhosis and hepatic insufficiency.
46 . The method according to claim 42 , wherein the pancreatic disease is selected from the group consisting of diabetes mellitus and pancreatitis.
47 . The method according to claim 42 , wherein the digestive tract system disease is selected from the group consisting of Crohn disease and ulcerative colitis.
48 . The method according to claim 42 , wherein the renal disease is selected from the group consisting of IgA nephropathy, glomerular nephritis and renal insufficiency.
49 . The method according to claim 42 , wherein the skin disease is selected from the group consisting of decubitus, burn injury, suture wound, lacerated wound, incision wound, bite wound, dermatitis, cicatricial keloid, keloid, diabetic ulcer, arterial ulcer and venous ulcer.
50 . The method according to claim 42 , wherein the lung disease is selected from the group consisting of pulmonary emphysema, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, sudden interstitial pneumonia (pulmonary fibrosis), diffuse pulmonary fibrosis, tuberculosis or asthma.
51 . The method according to claim 31 , wherein the polypeptide comprises the amino acid sequence represented by SEQ ID NO:1.
52 . The method according to claim 31 , wherein the polypeptide consists of an amino acid sequence in which at least one amino acid residue in the amino acid sequence represented by SEQ ID NO:1 is deleted, substituted and/or added, and has granulocyte colony-stimulating factor activity.
53 . The method according to claim 31 , wherein the polypeptide consists of an amino acid sequence having a homology of 80% or more with the amino acid sequence represented by SEQ ID NO:1, and has granulocyte colony-stimulating factor activity.
54 . The method according to claim 31 , wherein the polypeptide is a chemically modified polypeptide having granulocyte colony-stimulating factor activity.
55 . The method according to claim 31 , wherein the polypeptide is modified with polyalkylene glycol.
56 . The method according to claim 33 , wherein the CXCR4 inhibitor is AMD-3100 or a derivative thereof.